Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms.
Contact: HR@NeosTX.com
Contact: HR@NeosTX.com
Location: United States, Texas, Arlington
Employees: 201-500
Total raised: $56.1M
Founded date: 2008
Investors 2
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Presidio P... | presidiopa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.02.2015 | - | $20.6M | - |
| 23.04.2014 | Series C | $20M | - |
| 04.03.2014 | Series C | $15.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.07.2015 | New drug delivery methods are making taking medicine easier for everyone | Three dimensional printing technology is becoming more and more popular, from creating prosthetics to artificial organs. That same technology is also being used to create a new way to deliver medication. Aprecia Pharmaceuticals in Langhorne... |
| 25.02.2015 | Neos Therapeutics Completes $20.6M Funding Round | Neos Therapeutics, Inc., a Grand Prairie, TX-based specialty pharmaceutical company with a late-stage pipeline of innovative extended-release products for Attention-Deficit Hyperactivity Disorder (ADHD), completed a $20.6m round of funding.... |
| 25.02.2015 | Neos Therapeutics Completes $20.6 Million Financing to Further Advance its Late-Stage ADHD Product Pipeline | - |
| 23.04.2014 | Neos Therapeutics Announces $20 Million Loan Facility and Updated Total of $18 Million for its Additional Series C Financing | - |
| 23.04.2014 | Neos Therapeutics Announces $18M in Series C | GRAND PRAIRIE, Neos Therapeutics reported that the total amount raised in its Series C financing increased to $18 million from the $15.5 million previously announced. >> Click here for more funding data on Neos Therapeutics >&g... |
| 23.04.2014 | Neos Therapeutic Raises $22.5M | Neos Therapeutics, Inc., a Grand Prairie, TX-based oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, raised $22.5m in financing. It inc... |
| 10.03.2014 | Novel drug delivery could make ADHD medications easier for kids to take | Behind those products is its proprietary controlled-release oral disintegrating tablets and liquids. Chief Technology Officer Mark Tengler described to Xconomy that controlled release over time is crucial for ADHD drugs because they can’t b... |
| 05.03.2014 | Dallas Biotech Neos Therapeutics Raises $15.5M for ADHD Drugs | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Neos Therapeutics has raised $15.5 million in a Series C round of venture financing to further develop its controlled-release technology for ADHD medications. The biotech star... |
| 04.03.2014 | Neos Therapeutics Raises $15.5M in Series C Financing | Neos Therapeutics, Inc., a Grand Prairie, TX-based oral drug delivery company, raised $15.5m in Series C financing. Backers included Burrill Life Sciences Capital Fund III, CAC LLC, CMEA Capital, Crabtree Partners and Delaware Street Capita... |
| - | Novel drug delivery could make ADHD medications easier for kids to take | Neos Therapeutics is planning to make controlled-release ADHD medicines in liquid and dissolving tablet form, so they’re easier for children to take and last throughout the day. The Grand Prairie, Texas, company just rounded up $15.5 millio... |
Show more